Regeneron Pharmaceuticals, Inc. $REGN Stock Position Trimmed by South Dakota Investment Council

South Dakota Investment Council decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 12,162 shares of the biopharmaceutical company’s stock after selling 800 shares during the period. South Dakota Investment Council’s holdings in Regeneron Pharmaceuticals were worth $9,397,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. WPG Advisers LLC boosted its position in shares of Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 25 shares during the period. SHP Wealth Management acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $26,000. Titan Wealth CI Ltd acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $29,000. Kemnay Advisory Services Inc. bought a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $31,000. Finally, Birchwood Financial Partners Inc. bought a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $32,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.0%

Shares of REGN stock opened at $695.42 on Thursday. The stock has a 50-day simple moving average of $638.74 and a 200 day simple moving average of $711.76. The stock has a market capitalization of $73.52 billion, a P/E ratio of 16.94, a P/E/G ratio of 27.77 and a beta of 0.24. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. During the same period in the previous year, the business earned $8.22 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% compared to the same quarter last year. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 2.06 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Analyst Ratings Changes

REGN has been the subject of several recent analyst reports. HSBC decreased their price target on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research note on Monday, July 6th. Wells Fargo & Company decreased their target price on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a research report on Monday, May 18th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Canaccord Genuity Group dropped their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $641.00 price target (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $787.88.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Potentially solid quarterly results: Investors are looking for continued growth from Dupixent, Eylea HD and Libtayo, along with updates on buybacks and Regeneron’s development pipeline. The prior quarter showed strong momentum, with revenue rising 19% year over year and EPS exceeding analyst expectations. Regeneron To Report Earnings Tomorrow
• Positive Sentiment: Partnered Arcalyst momentum: Kiniksa Pharmaceuticals exceeded second-quarter expectations, supported by sales of Arcalyst, which is partnered with Regeneron. The update may reinforce confidence in the commercial performance and royalty contribution of the collaboration, although the impact on REGN is indirect. Kiniksa Tops Q2 Estimates on Regeneron-Partnered Arcalyst
• Neutral Sentiment: Earnings are the next major catalyst: Regeneron is scheduled to report before the market opens Thursday. Investors will focus on product sales, full-year guidance, pipeline commentary and management’s response to the recent clinical setback. Regeneron to Announce Earnings on Thursday
• Negative Sentiment: Failed melanoma trial and litigation overhang: Multiple law firms announced or promoted securities class actions alleging that Regeneron and executives misled investors about the Phase 3 Fianlimab-Libtayo trial, including its protocol changes and clinical differentiation. The trial failure reportedly caused a sharp selloff and an approximately $11 billion loss in market value. The lawsuits themselves may not create an immediate cash liability, but they add reputational, legal and pipeline risk. Investors have until September 14, 2026, to seek lead-plaintiff status. Regeneron Investor Alert

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.